

ADBRY® (tralokinumab-ldrm) & Pregnancy Study

Help Us Understand the Possible Effects of Adbry® in Pregnancy

Many people need to take medication during pregnancy to appropriately manage a chronic health condition. In some cases, avoiding or stopping medication use during pregnancy may be more harmful than taking medication. Yet fewer than 10% of medications have enough information to determine their safety for use in pregnancy — this is where you come in!

MotherToBaby is currently enrolling pregnant women in a study examining the use of Adbry® (tralokinumab-ldrm) to treat eczema (also known as atopic dermatitis) during pregnancy.

Are you currently pregnant? Did you take Adbry® at any point in your current pregnancy? If you answered “yes” to both of these questions, then you have the opportunity to help us learn more about Adbry® use in pregnancy.

“There is a huge need to generate more data for all of the drugs that people who are pregnant need to take.”

— Christina Chambers, PhD, MPH, Lead Investigator, MotherToBaby Pregnancy Studies

Will you take the next step and become our partner? Make an impact on the health of future families today by joining our Adbry® & Pregnancy Study!



UC San Diego

CENTER FOR BETTER BEGINNINGS

Join our ADBRY® (tralokinumab-ldrm) Study

Your information is confidential.

MotherToBaby Pregnancy Studies are conducted by the Organization of Teratology Information Specialists (OTIS) and coordinated by the University of California San Diego. MotherToBaby is listed as a resource for information about medications in pregnancy by the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC).

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, December 9, 2022.